|View printer-friendly version|
|June 15, 2018 8:00 a.m.|
|Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache|
Based on the study meeting the futility criteria, the Company will discontinue the trial for chronic cluster headache. Chronic Cluster Headache patients who participate in the long-term safety study, will discontinue their participation in the long-term safety study as well. The episodic cluster headache study is not affected and continues as planned.
“While we are disappointed with this outcome, we remain optimistic that
fremanezumab could have clinical benefits in additional conditions,
beyond migraine, where calcitonin gene-related peptide (CGRP) plays a
contributory role in their pathophysiology. We would like to thank the
patients and investigators for their participation in the Chronic
Cluster Clinical Trial,” said
Fremanezumab is currently under review by the
Fremanezumab is a monoclonal antibody targeting the CGRP (calcitonin
gene-related peptide) ligand, currently under review by the
Fremanezumab is also being investigated as a preventive treatment for several additional disorders including cluster headache and post traumatic headache disorder.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Fremanezumab, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
and other factors discussed in our Annual Report on Form 10-K for the
Teva Pharmaceutical Industries Ltd.